Drug Profile
Research programme: small molecule immunotherapy therapeutics - Active Biotech/Evotec SE
Latest Information Update: 25 Sep 2019
Price :
$50
*
At a glance
- Originator Active Biotech; Evotec AG
- Developer Active Biotech; Evotec SE
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Immunological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Germany
- 16 Jul 2016 No recent reports of development identified for research development in Immunological-disorders in Germany
- 12 Aug 2014 Evotec and Active Biotech further extend their Medicinal Chemistry collaboration